Segal R, Oh T, Ben-Joseph R, Russell W L
University of Florida, Gainesville 32610.
Hosp Formul. 1994 May;29(5):379-82, 388-91.
The objectives of this study were to determine (1) the expenditures of hospitals for IV histamine2-receptor antagonists (H2-RA), and (2) the cost savings that might be realized if only a single IV H2-RA was purchased for use. Forty hospitals provided data about purchase prices for each IV H2-RA dosage form purchased (cimetidine, ranitidine, and famotidine), the number of each dosage form used during the 12-month study period, purchase price and extent of usage for supplies, labor costs for preparing and administering IV H2-RAs, and IV H2-RA dosage schedules. The study showed that most hospitals were spending more money for IV H2-RAs than necessary given the pricing structures of the three products available to them at the time of this study. Also, that significant cost savings could be realized if a single H2-RA was used exclusively.
（1）医院静脉注射组胺2受体拮抗剂（H2-RA）的支出；（2）如果仅购买一种静脉注射H2-RA用于治疗可能实现的成本节约。四十家医院提供了有关所购买的每种静脉注射H2-RA剂型（西咪替丁、雷尼替丁和法莫替丁）的购买价格、在为期12个月的研究期间每种剂型的使用数量、供应品的购买价格和使用范围、制备和静脉注射H2-RA的劳动力成本以及静脉注射H2-RA的给药方案的数据。研究表明，鉴于本研究开展时可供医院使用的三种产品的定价结构，大多数医院在静脉注射H2-RA上的支出超出了必要水平。此外，如果专门使用单一的H2-RA，可实现显著的成本节约。
